Offstream
news

The Food and Drug Administration grants emergency use authorization for Merck & Co.'s antiviral COVID-19 oral pill named Molnupiravir for at-risk individuuals.
2021-12-23

The Food and Drug Administration gives full approval to the Pfizer–BioNTech COVID-19 vaccine, becoming the first vaccine in the U.S. to be granted full licensure and thereby giving businesses, schools and universities more confidence to adopt vaccine mandates.
2021-08-23

The U.S. Food and Drug Administration says that it has granted priority review for the vaccine developed by Pfizer and BioNTech. A decision on whether to fully approve the vaccine will likely be made within two months.
2021-07-16

White House COVID-19 Response Coordinator Jeff Zients says that the Biden administration will accelerate doses of the Pfizer-BioNTech and Moderna vaccines. The move comes after the United States suspended usage of the Johnson & Johnson vaccine.
2021-04-14

The United States suspends the use of the Johnson & Johnson vaccine following concerns of blood clots.
2021-04-13

South Africa voluntarily suspends its rollout of the Johnson & Johnson vaccine after the U.S. Food and Drug Administration recommended temporarily suspending use of the vaccine due to rare cases of blood clots.
2021-04-13

Johnson & Johnson's single-shot COVID-19 vaccine candidate meets the standards for emergency use authorization, according to analysis from a committee within the FDA, though formal authorization will not be determined until February 26. The vaccine is 66% effective in combating the virus and can be stored in normal refrigerators.
2021-02-24

An expert panel advising the FDA recommends granting Tozinameran emergency approval for usage in the United States.
2020-12-10

Pfizer and BioNTech apply for an emergency use authorization from the U.S. Food and Drug Administration for their vaccine. If the application is approved, the vaccine will likely be limited and rolled out in phases.
2020-11-20

President Donald Trump and the Food and Drug Administration (FDA) announce the emergency use authorization of convalescent plasma for COVID-19 patients after days of White House officials suggesting there were politically motivated delays by the FDA in approving a vaccine and therapeutics for the disease that President Trump claims has harmed his re-election chances. The FDA said more than 70,000 patients have been treated with convalescent plasma, but they have not yet obtained enough randomized clinical trial data on convalescent plasma for COVID-19. Some of those trials are underway.
2020-08-23